Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 6/20 | 1.00 |
| ▸ | ATP1B1 | P05026 | 6/20 | 1.00 |
| ▸ | ATP1A3 | P13637 | 6/20 | 1.00 |
| ▸ | ATP1B2 | P14415 | 6/20 | 1.00 |
| ▸ | ATP1A2 | P50993 | 6/20 | 1.00 |
| ▸ | ATP1B3 | P54709 | 6/20 | 1.00 |
| ▸ | FXYD2 | P54710 | 6/20 | 1.00 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | ZFP91 | Q96JP5 | 1/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.73 |
| ▸ | STAT3 | P40763 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.63 |
| ▸ | ATP12A | P54707 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bufalin SCHEMBL16628184 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL19415190 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL14477877 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL165666 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL20127236 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL23382204 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL15864888 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL21083171 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL21129737 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL8257006 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453713-B1 | BUFADIENOLIDE COMPOUNDS SUBSTITUTED IN POSITION 3 BY AN AMINE GROUP FOR USE IN THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10624883-B2 | Pulmonary hypertension preventative or therapeutic agent containing component exhibiting selenoprotein P activity-inhibiting effect | TOHOKU UNIVERSITY (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20190183882-A1 | PULMONARY HYPERTENSION PREVENTATIVE OR THERAPEUTIC AGENT CONTAINING COMPONENT EXHIBITING SELENOPROTEIN P ACTIVITY-INHIBITING EFFECT | TOHOKU UNIVERSITY (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3453713-A1 | BUFADIENOLIDE COMPOUNDS SUBSTITUTED IN POSITION 3 BY AN AMINE GROUP FOR USE IN THE TREATMENT OF CANCER | Neupharma, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2852285-B1 | BUFADIENOLIDE COMPOUNDS SUBSTITUTED IN POSITION 3 BY A HETEROCYCLIC AMINE FOR USE IN THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3296313-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Suzhou Neupharma Co., Ltd (CN) | 2018-03-21 | — | — | EP | disclosed |
| US-9572826-B2 | Compositions for the treatment of hair loss | BOURAS ELIAS (GB) | 2017-02-21 | — | — | US | disclosed |
| US-9572826-B2 | Compositions for the treatment of hair loss | BOURAS ELIAS (GB) | 2017-02-21 | — | — | US | disclosed |
| US-20110076328-A1 | COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | BOURAS ELIAS | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183882-A1 | PULMONARY HYPERTENSION PREVENTATIVE OR THERAPEUTIC AGENT CONTAINING COMPONENT EXHIBITING SELENOPROTEIN P ACTIVITY-INHIBITING EFFECT | SELENOI, GPX1, SCLY | ATP1A1 677/4885ATP1B1 900/4885ATP1A3 724/4885 |
| US-10624883-B2 | Pulmonary hypertension preventative or therapeutic agent containing component exhibiting selenoprotein P activity-inhibiting effect | SELENOI, GPX1, SCLY | ATP1A1 677/4885ATP1B1 900/4885ATP1A3 724/4885 |
| US-20110076328-A1 | COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | PSAP, GLA, GUSB | ATP1A1 1597/4885ATP1B1 974/4885ATP1A3 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.